Loading...
Loading...
MGTA| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 21.7M |
| Operating I/L | -21.7M |
| Other Income/Expense | 1.6M |
| Interest Income | -2.9M |
| Pretax | -20.2M |
| Income Tax Expense | 2.9M |
| Net Income/Loss | -23.1M |
Magenta Therapeutics, Inc. is a clinical-stage biotechnology company specializing in developing medicines for patients with blood cancers, genetic diseases, and autoimmune diseases. The company's primary focus is on the development of MGTA-117, an anti-CD117 antibody targeting hematopoietic stem cells and genetically mutated stem cells associated with acute myeloid leukemia and myelodysplastic syndromes. Additionally, they are working on a CD45-antibody drug conjugate for potential use in autoimmune diseases and hematology-oncology transplants, as well as MGTA-145 for autologous and allogeneic transplants. Magenta Therapeutics also has a cell therapy program, E478, for stem cell-based gene therapy and genome editing.
